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Background: Falls amongst people with Parkinson’s (PwP) result in significant disability and reduced quality of life.
There is emerging evidence that exercise-based and physiotherapeutic interventions are of benefit for improving fall
risk factors, such as balance. However, the benefit, in terms of preventing falls, is mixed. The development of effective
interventions has been identified as the highest research priority for this population.
The aim of this trial is to establish the effectiveness and cost-effectiveness of a novel, home-based physiotherapy
programme, compared with usual care, on falls amongst PwP.
Methods/Design: A UK multi-centre, community-based, single blind, randomised controlled trial with twelve month
follow-up, and nested economic evaluation and qualitative studies will be undertaken. Six hundred PwP who live in
their own home, have had one or more falls in the previous year and an MMSE score of ≥24 will be recruited. Those
living in care homes and those needing assistance from another person to walk indoors will not be eligible.
The intervention is a physiotherapist delivered, individually tailored and progressive, home-based programme
(PDSAFE) comprising task orientated movement strategy training, functional lower limb strengthening and balance
training, of six months duration. Unsupervised daily home exercises and strategies will be practised and supported
using technology. Control participants will receive usual care.
Data collection will include falls, cognitive state, balance and mobility, fear of falling, freezing of gait, mood, quality of
life, carer quality of life and resource use. Data will be collected at baseline, three, six and twelve months. Longitudinal
semi-structured interviews will be undertaken with forty participants to explore the expectations and experiences of
participants.
The primary outcome is risk of repeat falling at six months post-randomisation.
Discussion: The aims of this trial are to establish the effectiveness and cost-effectiveness of a novel, home-delivered
physiotherapy intervention (PDSAFE) compared with usual care on risk of falling for PwP who have a history of falling.
PDSAFE is a novel intervention that builds upon the existing literature and targeting known risk factors, being the first
study that uses a novel delivery modus (technology) in conjunction with traditional physiotherapeutic approaches.
Trial registration: Current Controlled Trials ISRCTN48152791
Keywords: Parkinson’s falls, Randomised, Physiotherapy, Exercise, Strategies* Correspondence: ann@soton.ac.uk
2University of Southampton, Southampton, UK
Full list of author information is available at the end of the article
© 2015 Goodwin et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Goodwin et al. BMC Neurology  (2015) 15:81 Page 2 of 9Background
In the UK, there are estimated to be around 127,000
people with Parkinson’s (PwP) [1]. The lifetime preva-
lence of Parkinson’s in the UK is two per thousand with
an annual incidence of nineteen per hundred thousand
population [2]. PwP are twice as likely to experience falls
when compared with the community-dwelling, older
population due to both physical and cognitive impair-
ments [3]. Falls and fall-related injuries have not been
identified separately within cost of illness studies in
Parkinson’s [4] but contribute to morbidity, hospital ad-
missions and reduced quality of life in this population
[5,6]. A national survey among the national Parkinson’s
Foundation Centres in the USA listed falls and fractures
as one of the top reasons for hospitalisation in this
population [7]. Similarly, an Australian study reviewed
645 admissions in which Parkinson’s was a secondary
diagnosis and identified falls and related fractures as the
leading reason for hospitalisation accounting for 13% of
the total cases [8]. A recent survey of a thousand PwP,
carers, and health and social care professionals reported
the development of interventions to reduce falls and im-
prove balance as the highest research priority [9].
A UK survey involving over 13,000 PwP indicated that
only 54% had ever seen a physiotherapist as part of their
management [10]. The prevention of a cycle of inactivity
and injurious falls is a global priority [11]. Despite a
wealth of evidence of effective interventions, in particu-
lar exercise, for reducing falls in the general older popu-
lation [12,13], the evidence to date for the prevention of
falls for PwP is mixed [14]. People with reduced balance
control and falls respond poorly to medication, the
mainstay of Parkinson’s management [15]. In a rando-
mised controlled trial of home-based physiotherapy with
142 participants, Ashburn et al. [16] demonstrated a
non-significant difference in fall risk at six months of −5%
(95 % CI −20 %, 10 %). Goodwin and colleagues [17]
compared a physiotherapist-led group strength and
balance programme plus additional home-based exer-
cises with usual care and reported a fall incident rate
ratio (IRR) of 0.74 (95 % CI 0.41, 1.33) at 20 weeks. A re-
cently published trial from Australia evaluating an inter-
vention that comprised progressive strength and balance
training and cueing strategies for six months also reported
a non-significant reduction in falls, however subgroup
analysis indicated the programme was effective for those
with lower disease severity [18]. An RCT of Tai Chi for
those with mild Parkinson’s was effective at reducing falls
as a secondary outcome [19]. Despite the limited evidence
for reducing falls, there is evidence of the benefit of
exercise on fall risk factors, such as impaired balance
[20] and of movement strategies to reduce freezing [21].
There is also a high probability of exercise interventions
being cost-effective for PwP [22].PwP have different risk factors for falling than the gen-
eral older population, including freezing of gait, cogni-
tive impairment and poor mobility [23]. A recent paper
[24] reported that ambulatory activity and the context in
which people fall contributes to the heterogeneous nature
of falls in PwP and that “one size fits all” interventions are
unlikely to be beneficial. Interventions therefore need to
be multimodal and individually tailored in order to be
effective.
The aim of this trial is to establish the effectiveness
and cost-effectiveness of a novel, home-based physiother-
apy programme called PDSAFE, compared with usual
care, on falls amongst PwP. A nested longitudinal qualita-
tive study additionally seeks to explore the views, expecta-
tions and experiences of trial participants, in order to
further explain findings of the trial.
Methods/Design
Trial design and setting
The trial is a UK multi-centre, community-based, single
blind, randomised controlled trial with twelve month
follow-up, with nested economic evaluation and qualita-
tive studies. The trial will be conducted at four sites:
Southampton, Portsmouth, Bournemouth /Poole and
Exeter. The primary outcome is risk of repeat falling
over the 6 month period. Ethical approval has been
given by the National Research Ethics Service - South
Central – Hampshire B (Reference 14/SC/0039). Trial
registration reference is ISRCTN48152791.
Participants
Participants will be eligible for the trial if they: (a) have a
confirmed consultant diagnosis of Parkinson’s; (b) live at
home; (c) have had one or more falls in the previous
year; (d) score ≥24 of the Mini-Mental State Examin-
ation (MMSE) [25]; (e) are able to understand and follow
instructions; (f ) are able to undertake an exercise
programme; (g) are able to give informed consent. Ex-
clusion criteria are: (a) living in a care home; (b) need
assistance from another person to walk indoors; or (c)
wheelchair bound or bedridden unless aided as defined
by Hoehn and Yahr Stage 5 [26].
Sample size
The primary outcome is the risk of repeat falling be-
tween 0–6 months. In a previous trial of PwP with two
or more falls in the previous year [16], the risk of repeat
falling at six months was 68 % (42/63) for controls
versus 56 % (35/63) in the exercise group. However, the
population in the proposed trial will include those with
one or more previous falls and we therefore anticipate
the risk of repeat falling to be lower. Assuming a control
group risk of repeat falling between 0–6 months to be
63 %, and 50 % in the intervention group, a sample size
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for analysis is indicated. Allowing for 10% drop out be-
tween agreeing to the 3 months pre-randomisation fall
data collection and randomisation, and 5 % of loss to
follow-up at 6 months amongst those randomised, a
total of 534 participants need to be recruited. We aim to
recruit 600 participants. Figure 1 provides a flow dia-
gram showing anticipated numbers at recruitment and
follow-up.
Recruitment
Potential participants will be identified from clinical reg-
isters of PD specialists at each site, research registers ofFigure 1 Trial flow diagramthose who have previously indicated interest in taking
part in future research, and from Parkinson’s UK local
groups, supported by the National Institute for Health
Research (NIHR) Clinical Research Network (CRN).
Those identified from clinical registers will be invited to
participate, in writing, by their specialist, and those
expressing an interest will be asked for permission to
pass their contact details onto the research team in
order that further information can be shared, and the
opportunity to participate offered. All potential partici-
pants will be provided with a Participant Information
Sheet, a reply slip and pre-paid envelope. On receipt,
those expressing interest will be contacted by telephone
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home visit (allowing at least 24 hours for consideration
before proceeding) to gain written informed consent and
complete screening measures. Once consent is gained,
demographic data, medical history, MMSE, Montreal
Cognitive Assessment (MoCA) [27], Hoehn & Yahr score
and number of falls in previous year will be collected and
participants will be given diaries to complete for three
months to prospectively record any fall events. Permission
at this time will also be sought to pass details of those
randomised to the intervention arm to a qualitative
researcher in order that contact can be made to discuss
involvement within the nested qualitative study (see
below). Where appropriate, carers will also be invited to
participate in the study and will be provided with a carer
information sheet. Recruitment commenced in July 2014.
Randomisation
Following baseline assessment, individuals will be rando-
mised in a 1:1 ratio to either intervention or control
arms, stratified by site, using random block size of 2, 4,
6 or 8 to ensure balance within each site, whilst main-
taining allocation concealment. The aim will be to
undertake the randomisation between thirteen and six-
teen weeks post baseline assessment after the comple-
tion of three months of pre-randomisation fall diaries.
The process will be coordinated by the UKCRC registered
Oxford Clinical Trials Unit. To ensure concealment, study
allocation will be undertaken using a password protected,
web-based portal with allocation only generated after
registration of each eligible participants. Randomisation
outcome will be e-mailed to the trial co-ordinating
centre and the details of allocation will be forwarded to
the physiotherapy team who will advise on the timescale
for their first visit which should be within two weeks
(maximum of four weeks).
Interventions
All trial participants will continue to receive usual care
as deemed by their care providers, including medical
and nurse specialist assessment and interventions, such
as medication management, as well as usual activities,
such as exercise or social groups. They will be encour-
aged to avoid changing their activity unless specifically
advised by a healthcare professional, as well as keep a
record of their usual care and activity and any exercise
classes outside of the trial for the duration of the study.
The central component of the PDSAFE intervention
is a physiotherapist delivered, individually tailored,
progressive home-based exercise programme to target
modifiable risk factors for falls, including freezing,
balance and mobility impairment and physical activity.
The programme was informed by the following work –
The FaME programme [28], the EXSart Trial [16], theOtago Exercise Programme [29], the PD-WEBB programme
[18], the GETuP trial [17], David et al. [30], Mayer et al. [31]
and the American College of Sports Medicine [32]. The
programme will be delivered by physiotherapists who will
undertake an assessment to identify impairments and ac-
tivities that will be addressed within the intervention
programme. The programme will comprise a warm up
session and three main active elements:
 Warm up and major muscle group stretches to
prepare the body for exercise and enable the body to
move more freely when exercising.
 Task-orientated movement strategy training to
improve freezing of gait and performance of
complex tasks specific to fall-related activities and
circumstances within the home environment. A
context and task specific evaluation of falls risk will
be undertaken to identify specific problematic areas
and strategies identified to address the problems.
Videos will be recorded by the therapist using a
tablet of the participant engaged in activities with
and without the use of strategies. Training will
include activities such as turning, and single and
dual tasks of complex functional activities. Tailored
video vignettes of strategies will be given to
participants on a DVD to remind and reinforce
between face-to-face sessions. This type of technology
has been shown to be of benefit for delivering fall
prevention exercises [33]. Participants will be asked to
practice the strategies daily and to integrate these into
daily functional tasks where possible.
 Functional lower limb strengthening exercises will
be progressive using bodyweight or a weighted vest,
maintaining intensity at a moderate-hard level as
assessed by the Borg Scale (Borg 1987).
 Dynamic balance exercises will be progressed
through more complex activities and varied starting
positions, postures and cognitive challenges
maintaining difficulty at a moderate to hard level.
An individualised booklet of exercises will be provided,
selected from a menu following assessment. If an indi-
vidual struggles in achieving a good technique the
physiotherapist will video record them doing the exer-
cises correctly using a tablet device. This recording will
be shared with the participant to provide them with an
accurate visual reference when practising. Participants
will be encouraged to perform all exercise components
daily. However, to avoid the possibility of overload, a
daily safety questionnaire is completed, that advises
participants which components to complete and which
to leave, due to the risk of fatigue or other safety issues.
The intervention will take place over a six-month
period and will consist of up to twelve, one hour face-
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face sessions will be delivered more intensely to start but
less frequently over time to maximise motivation and
promote independence. The exact delivery of these,
however, will be negotiated between the physiotherapist
and participant. This model of delivery is unique in exer-
cise studies for PwP. An example delivery model could
be:
 Twice a week for weeks 1–2
 Once a week on week 3, 4, and 5
 Once a month at 2, 3, 4, 5 and 6 months.
Participants in the control group will continue to
receive usual care and will be advised to continue any
activities in which they usually participate, but not to
commence new activities, if possible. In addition, they
will be visited once by a physiotherapist within four
weeks of completing pre-randomisation fall diaries and
provided with a DVD about Parkinson’s. After the twelve
month follow-up assessment has been completed, they
will receive written and verbal guidance on physical ac-
tivity and strategies by the physiotherapist.
Physiotherapist training
Physiotherapists will deliver the intervention in partici-
pants’ homes across the four study centres. In order to
minimise inter-therapist variation and enhance fidelity, a
detailed training programme has been developed thatTable 1 Data Collection
Method Scr
pre
MMSE [25] Researcher assessed x
Hoehn and Yahr Scale [26] x
MoCA [27] x
Mini BesTest [53]
Timed Chair Stand [54]
MDS-Unified Parkinson’s Disease Rating
Scale (UPDRS) - motor scale [55]
Falls Efficacy Scale International [56] Self-report (face-to-face)
EuroQoL (EQ-5D) [37]
New Freezing of gait questionnaire [57]
Parkinson’s Disease Questionnaire 39 [58]
Physical Activity Scale for the Elderly [59]
Geriatrics Depression Scale [60]
Carer Experience Scale (CES) [38]
Carer Strain Index (CSI) [39]
Health and Social Care resource use
Falls, near falls, fractures x
Adverse events xincludes clinical reasoning for prescribing the exercises
and strategies and practical delivery of the programme.
This is delivered in a two-day face-to-face session. Once
trained and delivering the intervention there will be
regular team meetings including masterclass sessions,
case studies, and weekly telephone support from the lead
physiotherapist.
Data collection
Pre-randomisation fall data
Participants will be asked to prospectively record falls
using a monthly diary for the three months between re-
cruitment and randomisation. This process will enable
participants to become familiar with the procedure for
recording falls and assist the research team with identi-
fying those participants who may need additional sup-
port to complete the diaries. In addition, the data will be
used in the main trial analysis as a covariate.
Baseline assessment
On completion of three months of pre-randomisation fall
data, an assessor will visit the participants (and carer) at
home to complete baseline data collection (Table 1) com-
prising functional activities, Parkinson’s severity, freezing,
quality of life, depression, fear of falling and physical activ-
ity. Information about current medication, social status
and rehabilitation input will also be collected. This assess-
ment will be undertaken prior to randomisation and the
assessor will be blinded to subsequent allocation.eening (3 months
-baseline)
Baseline 3 months 6 months 12 months
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
x x x x
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Follow up data (Table 1) will be collected at three,
six and twelve months post-randomisation during a
face-to-face visit to the participants’ home by an asses-
sor blinded to group allocation. Serious adverse events
(SAE) have been defined as hospitalisation as a result
of a fall directly linked to the treatment with a the-
rapist or whilst doing it on their own. Previous experi-
ence within the team suggests that participants may
inadvertently unblind assessors. We aim to minimise
this through explicit reminders prior to assessment
visits. We will also ask assessors to record their esti-
mate of which study arm they believe participants have
been allocated to, and their confidence in that belief at
the end of the trial. This will enable us to examine the
extent of unblinding. Assessments will last approxi-
mately 90 minutes and, where possible, all assessments
for an individual will be arranged for a similar time
of day at mid-medication cycle when movement is
optimal.
Fall data will be collected using monthly, prospective,
self-report diaries for twelve months following random-
isation and will include falls, near falls and injuries [34].
In addition to the diary, participants will be provided
forms to completed details of any falls such as location
and subsequent treatment [35]. The diaries will be deliv-
ered by the assessor at assessment visits and returned
each month in a pre-paid envelope and with telephone
reminders when not received within three weeks.
The implementation of the intervention protocol in
terms of quality and dose will be monitored [36]. Joint
patient sessions will be undertaken with the lead physio-
therapist to assess intervention fidelity. Participant adher-
ence to the unsupervised programme will be established
by them completing a daily tick sheet of the exercises they
have completed.
For the economic evaluation, resource use (health and
social care) and carer data will be collected using a tick
box resource sheet aided by a resource use diary.
Additional resource use will be collected within the fall
dairies. Information on hospital admissions, length of
stay, ambulance call outs, A&E attendances, GP and spe-
cialist appointments, physiotherapy, occupational therapy
and admission to a care home will be identified and mea-
sured. Costs of implementing PDSAFE include training,
time to deliver the intervention (face-to-face and tele-
phone), travel, equipment and DVD production will also
be identified and measured. Participant quality of life
(QOL) data will be collected using the EuroQOL EQ-5D
instrument [37] during assessment visits to enable the
measurement of Quality Adjusted Life Years (QALYs). To
capture any potential spillover QOL impacts carer data
will collected using the Carer Experience Scale (CES) [38]
and the Caregiver Strain Index (CSI) [39].Statistical analysis
The main analysis will be based on intention to treat in
that participants will be analysed according to the group
to which they were allocated irrespective of the extent of
intervention received. The primary outcome, risk of
repeat falling over the 6 month period after randomisa-
tion, will be compared between intervention and control
groups using a logistic regression model including falling
during the pre-randomisation monitoring period, Hoehn
and Yahr score, and centre as covariates, with the defin-
ition of the falling covariate decided at blind review of
the data prior to analysis.
Repeat falling during 6–12 months and other binary
secondary outcomes will be examined using logistic re-
gression models similar to that for the primary outcome.
The rates of falling over 0–6 months and over 6–12
months will be examined in negative binomial models
including baseline rate of falling over the 3 month
pre-randomisation falls collection period, Hoehn and
Yahr score, and centre as covariates, fitted using either
the nbreg or xtpoisson regression commands in Stata
(Statacorp, TX, USA). In the negative binomial model,
the effect of the intervention is summarised as a falls
incidence rate ratio (IRR) (intervention/control) with ra-
tios below 1.00 indicative of lower rates in the interven-
tion group. All participants in the main trial will have
been asked to complete the baseline three months falls
collection, and the length of follow-up time over which
falls events are collected between 0–6 months and 6–12
months post randomisation will be included as exposure
times in the regression. Rates of falling in each of the
three month periods between the pre-randomisation
period and 12 months in the intervention and control
groups will be displayed graphically. Other secondary
outcomes will be examined in mixed normal models for
repeated measurements at 3, 6 and 12 months control-
ling for centre, Hoehn and Yahr score, and baseline
value, including participants with incomplete follow-up
information in the analysis. No formal interim analyses
are planned.
Sensitivity analyses will be conducted to examine the
impact of missing data due to causes other than death,
using worst-case and other single imputation on conclu-
sions. Since only participants successfully completing
the initial three months falls diary collection period will
be entered into the main trial, this should minimise loss
of diary information on which the primary outcome is
based.
Pre-planned subgroup analyses of the primary out-
come will be performed with subgroups of participants
defined by disease severity, phenotype and cognitive
impairment, with subgroups specified without reference
to the treatment allocation variable and before the blind
is broken. The significance of any difference in treatment
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interaction. We will also examine the effect of the inter-
vention separately in each centre. The extent of interven-
tion that was received by participants will be described.
A secondary per-protocol analysis of the main treat-
ment effect will be conducted, restricting the parti-
cipants included in the intervention group to those
receiving an adequate extent of the intervention, to be
decided a priori. If we fail to show a statistically signifi-
cant difference in the primary ITT analysis, the per-
protocol analysis will help in understanding whether the
lack of significance resulted from dilution of the treat-
ment effect. Exploratory analysis of the outcome in rela-
tion to the main components of the intervention will
also be undertaken.
Economic analysis
Readily available unit costs [40] will be attached to all
items of resource use and a mean cost per participant
estimated. QALYs will be calculated using EQ-5D with
incremental cost and incremental benefits (effective-
ness and utility) reported within an incremental cost-
effectiveness ration (ICER). In addition, in line with the
primary outcome measure, the economic evaluation
will estimate the incremental cost-per-fall averted.
Carer QOL will be calculated and reported separately.
The evaluation will adhere to guidelines for good eco-
nomic evaluation practice [41,42]. Analyses of costs
and effects will be undertaken in Stata adhering to good
practice for economic evaluations alongside clinical tri-
als [43,44]. Missing cost and QOL data will be explored
by employing multiple imputation methods [45,46]
using alternative configurations of baseline covariates.
The economic evaluation will be reported according to
recent guidance [47].
Nested qualitative study
A longitudinal qualitative study will be conducted along-
side the main trial to explore the impact of Parkinson’s
on daily life and the expectations and experiences of par-
ticipants allocated to the intervention study arm. The
study will draw on the principles of grounded theory
[48,49] and use a maximum variation sampling strategy
[50] addressing age (≤ 80 years; > 80 years), gender, falls
in previous year (1 fall; 2–10 falls; > 10 falls), disease
severity (each of Hoehn and Yahr stages 1–4) and centre
(Southampton, Portsmouth, Bournemouth, Exeter). Semi-
structured interviews [51] using a topic guide will be
conducted with forty participants (ten from each study
site) or as many as needed to ensure data saturation,
from the intervention arm of the study, in their own home.
Each participant will be interviewed twice, firstly after
screening but before the intervention commences, and
secondly, six months after completion of the intervention.All interviews will be digitally recorded, transcribed
verbatim and supplemented by a researcher diary [52].
Analysis will comprise initial, focused, axial and theo-
retical coding in order to develop interpretive theories
conceptualising the experience of participating in
PDSAFE. The qualitative researcher will keep a re-
search diary throughout, and will compare coding of
initial interviews with a second researcher to promote
sensitivity and reflexivity [52]. Supervisory meetings
will ensure that preliminary interpretation is open to
scrutiny, and that each iteration is shared and tracked.
These strategies will help to ensure that rigour is main-
tained in the conduct and analysis of this sub-study.
Along with self-reported dairies of home exercises, the
longitudinal qualitative study will contribute more de-
tailed information about factors influencing adherence.
Discussion
The physical, psychological and economic consequences
of falls among PwP are costly in both human and finan-
cial terms. This aims of this trial are to establish the
effectiveness and cost-effectiveness of a novel, home-
delivered physiotherapy intervention (PDSAFE) com-
pared with usual care on risk of falling for people with
Parkinson’s who have a history of falling.
PDSAFE is a novel intervention that builds upon the
existing literature and targeting known risk factors, being
the first trial that uses a novel delivery modus (technology)
in conjunction with traditional physiotherapeutic ap-
proaches. This will be the largest trial of aiming to reduce
falls for PwP to date. The inclusion of a nested qualitative
study will aid understanding of the processes and mecha-
nisms of the intervention and outcomes.
If effective, this intervention has the potential to im-
prove the physiotherapy care and therefore patient and
service level outcomes for PwP.
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